Vectura wins additional $10m patent damages against GSK
16-09-2019
GSK awarded Arrow declaration in patent dispute with Vectura
17-12-2018
Vectura sues GSK for patent infringement
29-07-2016
Willy Barton / Shutterstock.com
British drugmaker Vectura has succeeded in its patent litigation against fellow UK pharmaceutical company GlaxoSmithKline (GSK) over a series of drugs delivered through GSK’s ‘Ellipta’ dry powder inhaler.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
Vectura, GlaxoSmithKline, Ellipta, asthma, patent infringement, chronic obstructive pulmonary disease, damages, royalties, Delaware
